GlassScriptPhysician profile
Rossana Y Carter
NPI 1912089251
$5,444.34
in general payments reported to CMS, 2019-2025
43 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $705 · 2021: $837 · 2022: $375 · 2023: $559 · 2024: $1,208 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,961.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $740.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $582.02 | 2020-2025 | Vraylar, Qulipta |
| Amgen INC. | $557.76 | 2019-2025 | Evenity, Repatha, Repatha |
| Pfizer INC. | $515.66 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $477.18 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $283.89 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.55 | 2020-2024 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $228.88 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.46 | 2019-2025 | Jardiance, Synjardy |
| Astellas Pharma US INC | $143.59 | 2019-2023 | Veozah |
| Esperion Therapeutics, INC. | $130.03 | 2021-2024 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $127.53 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.10 | 2024 | |
| Glaxosmithkline, LLC. | $84.96 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Allergan, INC. | $78.52 | 2019-2020 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $77.98 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Idorsia Pharmaceuticals US INC | $73.21 | 2023-2024 | Quviviq |
| Dexcom, INC. | $73.06 | 2021-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $72.39 | 2025 | Korlym |
| Radius Health, INC. | $57.26 | 2020 | |
| Seqirus USA INC | $50.06 | 2021-2025 | Flucelvax, Fluad |
| Ardelyx, INC. | $49.79 | 2024-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $47.69 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $40.62 | 2024-2025 | Rexulti |
| Eisai INC. | $38.75 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.95 | 2022 | |
| Abbott Laboratories | $36.68 | 2023-2025 | Freestyle Libre, Freestyle Libre 3 |
| Medtronic, INC. | $36.41 | 2025 | Kyphon Express II Kyphopak Tray |
| Kowa Pharmaceuticals America, INC. | $33.47 | 2020 | |
| Kerecis Limited | $26.58 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Teva Pharmaceuticals USA, INC. | $25.45 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $24.93 | 2025 | |
| Bausch Health US, LLC | $22.37 | 2021 | |
| Lundbeck LLC | $18.82 | 2025 | Rexulti |
| Ibsa Pharma INC. | $17.45 | 2025 | Licart, Tirosint, Flector |
| Boston Scientific Corporation | $17.02 | 2024 | Xpeeda Dsl Fiber |
| Amneal Pharmaceuticals LLC | $16.78 | 2023 | Unithroid |
| Jazz Pharmaceuticals INC. | $16.30 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.83 | 2019 | |
| Xeris Pharmaceuticals, INC. | $14.99 | 2021 | |
| Endo Pharmaceuticals INC. | $14.47 | 2021 | |
| Currax Pharmaceuticals LLC | $14.04 | 2025 | Contrave |
| Exact Sciences Corporation | $13.29 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rossana Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.